

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

We claim:

1. (CURRENTLY AMENDED) A method for stimulating angiogenesis in a tissue comprising administering to said tissue an angiogenesis stimulating amount of a pharmaceutical composition comprising ~~an adiponectin protein or angiogenic stimulating portion thereof in a pharmaceutically acceptable carrier or~~ a nucleic acid cassette containing a nucleic acid encoding for adiponectin or angiogenic stimulating portion thereof operably linked to promoter.
2. (PREVIOUSLY PRESENTED) The method of claim 1, wherein the promoter is inducible.
3. (PREVIOUSLY PRESENTED) The method of claim 1, wherein said tissue has a disease or disorder associated with insufficient angiogenesis.
4. (PREVIOUSLY PRESENTED) The method of claim 3, wherein the disease or disorder results in abnormal circulation.
5. (PREVIOUSLY PRESENTED) The method of claim 3, wherein said tissue is myocardial.
6. (PREVIOUSLY PRESENTED) The method of claim 3, wherein said disorder is a cardiac disorder.
7. (WITHDRAWN) The method of claim 1, wherein the adiponectin protein is a trimer.

8. (CURRENTLY AMENDED) A method for treating a cardiac disorder comprising administering to a patient having said disorder a pharmaceutical composition comprising ~~adiponectin protein or effective portion thereof~~ or a nucleic acid cassette containing a nucleotide sequence encoding adiponectin or effective portion thereof, operably linked to a promoter.
9. (PREVIOUSLY PRESENTED) The method of claim 8, wherein said cardiac disorder is associated with abnormal circulation.
10. (PREVIOUSLY PRESENTED) The method of claim 8, wherein said cardiac disorder is cardiac myopathy.
11. (WITHDRAWN) The method of claim 8, wherein the adiponectin protein is a trimer.
12. (PREVIOUSLY PRESENTED) The method of claim 8, wherein the promoter is inducible.
13. (WITHDRAWN) A kit for stimulating angiogenesis or treating a cardiac disorder in a target mammalian tissue comprising a composition comprising a nucleic acid cassette containing a nucleic acid segment encoding for adiponectin operably linked to a promoter or a pharmaceutical composition of adiponectin protein or effective portion thereof and a pharmaceutically acceptable carrier or excipient.
14. (WITHDRAWN) The kit of claim 13, wherein said tissue has a disease or disorder associated with insufficient angiogenesis.
15. (WITHDRAWN) The kit of claim 14, wherein the disorder is a cardiac disorder.
16. (WITHDRAWN) The kit of claim 13, wherein the cardiac disorder is selected from the group consisting of myocardial infarction, cardiac hypertrophy, and cardiac myopathy.

17-19 (CANCELED)

20. (PREVIOUSLY PRESENTED) The method of claim 3, wherein the disease or disorder is selected from the group consisting of a hypoxic tissue, an ulcer, an ischemic limb, diabetes, ischemic bowel syndrome, impotence, peripheral vascular disease, vasculitis, ischemic vascular disease, peripheral arterial occlusive disease, cerebrovascular disease and wound.

21. (PREVIOUSLY PRESENTED) The method of claim 10, wherein the cardiac myopathy is ischemic.

22. (PREVIOUSLY PRESENTED) The method of claim 22, wherein the ischemic cardiac myopathy is selected from the group consisting of myocardial infarct, atherosclerosis, coronary artery disease, and coronary artery insufficiency.

23. (PREVIOUSLY PRESENTED) The method of claim 10, wherein the cardiac myopathy is cardiac hypertrophy.